AR017664A1 - Formulaciones farmaceuticas de liberacion sostenida que contienen inhibidores de la alfa-glucosidasa y su uso para la manufactura de un medicamento - Google Patents

Formulaciones farmaceuticas de liberacion sostenida que contienen inhibidores de la alfa-glucosidasa y su uso para la manufactura de un medicamento

Info

Publication number
AR017664A1
AR017664A1 ARP980105946A ARP980105946A AR017664A1 AR 017664 A1 AR017664 A1 AR 017664A1 AR P980105946 A ARP980105946 A AR P980105946A AR P980105946 A ARP980105946 A AR P980105946A AR 017664 A1 AR017664 A1 AR 017664A1
Authority
AR
Argentina
Prior art keywords
manufacture
pharmaceutical formulations
glucosidase inhibitors
medicinal product
alfa
Prior art date
Application number
ARP980105946A
Other languages
English (en)
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of AR017664A1 publication Critical patent/AR017664A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Formulaciones farmacéuticas de liberacion sostenida de inhibidores de la alfa-glucosidasa como, por ejemplo, acarbosa, miglitol, emiglitatos o voglibosa,que conducen a una reduccion de efectos secundarios y uso de los mismos para la manufactura de unmedicamento.
ARP980105946A 1997-11-25 1998-11-24 Formulaciones farmaceuticas de liberacion sostenida que contienen inhibidores de la alfa-glucosidasa y su uso para la manufactura de un medicamento AR017664A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6669897P 1997-11-25 1997-11-25

Publications (1)

Publication Number Publication Date
AR017664A1 true AR017664A1 (es) 2001-09-12

Family

ID=22071124

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980105946A AR017664A1 (es) 1997-11-25 1998-11-24 Formulaciones farmaceuticas de liberacion sostenida que contienen inhibidores de la alfa-glucosidasa y su uso para la manufactura de un medicamento

Country Status (5)

Country Link
JP (1) JP2001523704A (es)
AR (1) AR017664A1 (es)
AU (1) AU1234399A (es)
WO (1) WO1999026606A2 (es)
ZA (1) ZA9810710B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL143225A (en) * 2000-05-24 2008-03-20 Pfizer Preparation of drugs containing α-amylase inhibitors to treat hyperacidity of the inner abdomen
GB0203296D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
NZ538117A (en) 2002-08-08 2007-01-26 Kissei Pharmaceutical Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
US7375113B2 (en) 2004-03-04 2008-05-20 Kissei Pharmaceutical Co., Ltd. Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
CN102631332A (zh) * 2012-04-28 2012-08-15 邹立兴 一种伏格列波糖片剂及其制备方法
CN104013590A (zh) * 2014-05-09 2014-09-03 万特制药(海南)有限公司 一种含阿卡波糖的药物组合物及其制备方法
WO2016001843A1 (en) * 2014-06-30 2016-01-07 Sun Pharmaceutical Industries Limited Extended-release gastroretentive tablets of voglibose
PE20171243A1 (es) * 2014-12-17 2017-08-24 Empros Pharma Ab Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados
CN110898025A (zh) * 2019-12-12 2020-03-24 湖北欣泽霏药业有限公司 阿卡波糖缓释制剂及其制备方法
CN111265489A (zh) * 2020-03-10 2020-06-12 乐普制药科技有限公司 一种可分割型阿卡波糖微丸缓释片剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134591A1 (de) * 1981-09-01 1983-03-10 Bayer Ag, 5090 Leverkusen Neue arzneimittelpraeparationen fuer glykosidhydrolasen-inhibitoren
AU596961B2 (en) * 1985-03-08 1990-05-24 Takeda Chemical Industries Ltd. Saccharide digestion inhibiting composition
DE68905424T2 (de) * 1988-08-22 1993-06-24 Takeda Chemical Industries Ltd Alpha-glucosidaseinhibitor zur foerderung der calciumabsorption.
TW272942B (es) * 1993-02-10 1996-03-21 Takeda Pharm Industry Co Ltd

Also Published As

Publication number Publication date
JP2001523704A (ja) 2001-11-27
WO1999026606A2 (en) 1999-06-03
WO1999026606A3 (en) 1999-08-12
ZA9810710B (en) 1999-06-14
AU1234399A (en) 1999-06-15

Similar Documents

Publication Publication Date Title
AR011069A1 (es) Compuestos amidino, proceso para su preparacion, compuestos intermediarios, formulaciones farmaceuticas que los comprenden, y su uso en la fabricacion de un medicamento como inhibidor de la oxido nitrico sintasa inducible.
AR012671A1 (es) Composiciones farmaceuticas para el tratamiento o profilaxis de la constipacion, los usos de dichas composiciones y los procesos para prepararlos
ES2113444T3 (es) Medicamentos.
UY26372A1 (es) "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen "
ES2196377T3 (es) Derivados de naftiridina.
ES2054860T5 (es) Derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion y su utilizacion como medicamentos.
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
CR7362A (es) Formulaciones farmaceuticas de derivado de platino
ES2161085T3 (es) Formulaciones que contienen oxaliplatino.
UY26258A1 (es) Derivados de 8-fenil-6,9-dihidro-[1,2,4] triazolo [3,4-i] purin-5-ona.
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
AR012125A1 (es) UNA SAL DE UN COMPUESTO DERIVADO DEL ÁCIDO NAFTIRIDINA CARBOXíLICO , SU USO PARA LA FABRICACIoN DE UN MEDICAMENTO , PROCEDIMIENTO PARA PREPARARLA Y UNA COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE
AR032293A1 (es) Estuche farmaceutico
AR017664A1 (es) Formulaciones farmaceuticas de liberacion sostenida que contienen inhibidores de la alfa-glucosidasa y su uso para la manufactura de un medicamento
GT200000077A (es) Sal mutua de amlodipino y atorvastatina
ES2160680T3 (es) Utilizacion de un antagonista de sustancia p en una composicion farmaceutica.
UY25192A1 (es) Formulación medicamentosa con liberación controlada de sustancia activa
UY26371A1 (es) Imidazo-3-il-aminas biciclicas, procedimiento para su preparacion y medicamentos que las contienen
ES2171691T3 (es) Derivados de la colchicina, uso de los mismos y formulaciones que los contienen.
AR021843A1 (es) Derivados de propanolamina sustituidos con heterociclos, procedimiento para su preparacion, y su utilizacion.
AR028448A1 (es) Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares
AR021086A1 (es) Omega-amidas de n-arilsulfonil-aminoacidos, un procedimiento para su preparacion, medicamento, uso de dichos compuestos para la preparacion de un medicamento y procedimiento para la preparacion de un medicamento.
ES2066390T3 (es) Nuevos derivados del espiro-(4.5)-decano, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR025351A1 (es) Agonistas retinoides selectivos par